GlassScriptPhysician profile
Anna M Scigacz
NPI 1376905307
$2,636.90
in general payments reported to CMS, 2019-2025
20 companies · $503 in 2025
The $503 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49.29 · 2020: $174 · 2021: $367 · 2022: $353 · 2023: $437 · 2024: $753 · 2025: $503.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,693.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,693.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $591.07 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $336.40 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $302.80 | 2020-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Amgen INC. | $231.06 | 2020-2024 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $220.74 | 2022-2025 | Jardiance |
| Abbvie INC. | $179.35 | 2023-2025 | Qulipta, Ubrelvy |
| Otsuka America Pharmaceutical, INC. | $168.97 | 2023-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $153.57 | 2020-2025 | Farxiga, Flumist Quadrivalent, Airsupra |
| Janssen Pharmaceuticals, INC | $131.02 | 2021-2024 | Xarelto |
| Pfizer INC. | $58.73 | 2019-2020 | |
| Madrigal Pharmaceuticals | $48.18 | 2025 | Rezdiffra |
| Astellas Pharma US INC | $37.94 | 2020-2023 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $30.13 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $27.27 | 2022 | |
| Shield Therapeutics INC | $24.14 | 2023 | Accrufer |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $22.34 | 2023 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $21.20 | 2022 | |
| Phathom Pharmaceuticals, INC. | $19.85 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.12 | 2024 | Xifaxan |
| Amarin Pharma, INC. | $15.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Scigacz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.